Results 131 to 140 of about 1,414,086 (297)
The chemistry of non-steroidal anti-inflammatory agents [PDF]
, 1969 Karl J. Doebel
openalex +1 more source
Epitope Mapping of Anti‐Neurofascin 155 Antibody in a Large Cohort of Autoimmune Nodopathy Patients
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Autoimmune nodopathy (AN), a newly recognized disease entity, is an immune‐mediated polyneuropathy involving autoantibodies against cell adhesion molecules located in nodes of Ranvier and paranodal regions, such as neurofascin 186 (NF186) and neurofascin 155 (NF155). The present study aimed to identify the epitopes for autoantibodies
Amina A. Abdelhadi +6 more
wiley +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background and Objectives Ofatumumab, a fully human anti‐CD20 monoclonal antibody, is effective in reducing relapses and disability progression in patients with multiple sclerosis. This study aimed to examine immune profile changes associated with ofatumumab in a prospective cohort of Chinese patients with relapsing–remitting multiple ...
Shu Yang +9 more
wiley +1 more source
The anti-inflammatory properties of tiotropium [PDF]
The Lancet Respiratory Medicine, 2018 Benfante, Alida +2 more
openaire +2 more sources
Anti-inflammatory potential of Empagliflozin [PDF]
Inflammopharmacology, 2021 openaire +3 more sources
Effects of some anti-inflammatory agents on scald oedema reaction in rat and mouse
, 1969 Hideo Nakamura, Keiji Nakamura
openalex +2 more sources
ANTI‐INFLAMMATORY AND RELATED PROPERTIES OF 4‐(P‐BIPHENYLYL)‐3‐HYDROXYBUTYRIC ACID [PDF]
, 1968 Denís Barron +2 more
openalex +1 more source
CSF Tau Is a Biomarker of Hippocampal Injury in Cryptogenic New‐Onset Refractory Status Epilepticus
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Cryptogenic new‐onset refractory status epilepticus (cNORSE) is a devastating condition characterized by the de novo onset of status epilepticus with unclear etiology. The identification of relevant early biomarkers in cNORSE is important to elucidate pathophysiology, aid clinical decision‐making, and prognosticate outcomes in cNORSE.
Yihui Goh +8 more
wiley +1 more source
ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective This phase 3b, open‐label, randomized ADAPT NXT study investigated the efficacy, safety, and tolerability of efgartigimod administered in either a fixed cycles dosing regimen (3 cycles of 4 once‐weekly infusions, with 4 weeks between cycles) or a cycle followed by every‐other‐week (Q2W) dosing.
Ali A. Habib +16 more
wiley +1 more source